Laboratory Monitoring of Heparin Anticoagulation in Hemodialysis : Rationale and Strategies
Copyright © 2023. Published by Elsevier Inc..
Unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs) are commonly used to prevent clotting of the hemodialysis extracorporeal circuit and optimize hemodialysis adequacy. There is no consensus on the optimal dosing for UFH and LMWHs during hemodialysis. In clinical practice, semiquantitative clotting scoring of the dialyzer and venous chamber may help to guide UFH and LMWH dose adjustment. Laboratory monitoring has not been shown to improve clinical outcomes and is therefore not routinely indicated in most hemodialysis patients. It might, however, be considered in select patients, such as those with extremes of body weight or history of repeated clotting or bleeding. Methods for laboratory monitoring include the activated partial thromboplastin time, activated clotting time, and antifactor Xa assays for UFH and antifactor Xa assay for LMWHs. Target ranges for anticoagulation in hemodialysis have been suggested but not clearly defined. When utilizing these tests, issues such as availability, standardization, interfering factors, and interpretation must be considered. In this narrative review, we discuss the rationale and methods of monitoring anticoagulation in hemodialysis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Seminars in nephrology - (2024) vom: 29. Jan., Seite 151477 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chiasakul, Thita [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ACT |
|---|
| Anmerkungen: |
Date Revised 30.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.semnephrol.2023.151477 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367812843 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367812843 | ||
| 003 | DE-627 | ||
| 005 | 20240131232215.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240131s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.semnephrol.2023.151477 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1276.xml |
| 035 | |a (DE-627)NLM367812843 | ||
| 035 | |a (NLM)38290962 | ||
| 035 | |a (PII)S0270-9295(23)00187-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chiasakul, Thita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Laboratory Monitoring of Heparin Anticoagulation in Hemodialysis |b Rationale and Strategies |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023. Published by Elsevier Inc. | ||
| 520 | |a Unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs) are commonly used to prevent clotting of the hemodialysis extracorporeal circuit and optimize hemodialysis adequacy. There is no consensus on the optimal dosing for UFH and LMWHs during hemodialysis. In clinical practice, semiquantitative clotting scoring of the dialyzer and venous chamber may help to guide UFH and LMWH dose adjustment. Laboratory monitoring has not been shown to improve clinical outcomes and is therefore not routinely indicated in most hemodialysis patients. It might, however, be considered in select patients, such as those with extremes of body weight or history of repeated clotting or bleeding. Methods for laboratory monitoring include the activated partial thromboplastin time, activated clotting time, and antifactor Xa assays for UFH and antifactor Xa assay for LMWHs. Target ranges for anticoagulation in hemodialysis have been suggested but not clearly defined. When utilizing these tests, issues such as availability, standardization, interfering factors, and interpretation must be considered. In this narrative review, we discuss the rationale and methods of monitoring anticoagulation in hemodialysis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ACT | |
| 650 | 4 | |a Anticoagulants | |
| 650 | 4 | |a aPTT | |
| 650 | 4 | |a anti-Xa | |
| 650 | 4 | |a monitoring | |
| 650 | 4 | |a renal dialysis | |
| 700 | 1 | |a Mullier, François |e verfasserin |4 aut | |
| 700 | 1 | |a Lecompte, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Cuker, Adam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Seminars in nephrology |d 1993 |g (2024) vom: 29. Jan., Seite 151477 |w (DE-627)NLM012626317 |x 1558-4488 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:29 |g month:01 |g pages:151477 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.semnephrol.2023.151477 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 29 |c 01 |h 151477 | ||